Ibrutinib in mantle cell lymphoma patients: Glass half full? Evidence and opinion

Deborah M. Stephens, Stephen Spurgeon

Research output: Contribution to journalReview article

14 Citations (Scopus)

Abstract

Mantle cell lymphoma (MCL) is a rare subtype of non-Hodgkin's lymphoma typically marked by an aggressive clinical course and a predilection for relapse. The B-cell receptor (BCR) signaling survival pathway is chronically activated in MCL, contributing to its pathogenesis. Ibrutinib is an inhibitor of Bruton's tyrosine kinase, a vital component of this pathway. This article details the current clinical experience with ibrutinib in the treatment of patients with MCL, including completed and published clinical trials and reviews potential adverse events (AEs) and pitfalls associated with ibrutinib therapy. Although most AEs experienced by patients treated with ibrutinib are mild, some can be severe and treatment limiting and may be attributed to off-target effects. Ibrutinib is a very promising agent for patients with MCL with notable response rates. However, when used as a single agent, around one third of patients relapse in the first 2 years of treatment. Recently reported combination therapies have shown significant activity. Emerging data evaluating potential mechanisms of drug resistance and the poor clinical outcomes after treatment failure are also discussed. Further understanding of resistance and its implications not only in relapsed disease but in the frontline setting are needed. Investigation of strategies to overcome resistance remains an area of high unmet clinical need. Evaluation of the impact of shorter treatment duration, effects on minimal residual disease, and incorporation of novel combinations are also warranted.

Original languageEnglish (US)
Pages (from-to)242-252
Number of pages11
JournalTherapeutic Advances in Hematology
Volume6
Issue number5
DOIs
StatePublished - 2015

Fingerprint

Mantle-Cell Lymphoma
Glass
Therapeutics
Recurrence
Residual Neoplasm
Proxy
Treatment Failure
Drug Resistance
Non-Hodgkin's Lymphoma
PCI 32765
B-Lymphocytes
Clinical Trials
Survival

Keywords

  • adverse events
  • ibrutinib
  • mantle cell lymphoma
  • resistance

ASJC Scopus subject areas

  • Hematology

Cite this

Ibrutinib in mantle cell lymphoma patients : Glass half full? Evidence and opinion. / Stephens, Deborah M.; Spurgeon, Stephen.

In: Therapeutic Advances in Hematology, Vol. 6, No. 5, 2015, p. 242-252.

Research output: Contribution to journalReview article

@article{b027eec8dbd84eec8b1661dfcd015ca8,
title = "Ibrutinib in mantle cell lymphoma patients: Glass half full? Evidence and opinion",
abstract = "Mantle cell lymphoma (MCL) is a rare subtype of non-Hodgkin's lymphoma typically marked by an aggressive clinical course and a predilection for relapse. The B-cell receptor (BCR) signaling survival pathway is chronically activated in MCL, contributing to its pathogenesis. Ibrutinib is an inhibitor of Bruton's tyrosine kinase, a vital component of this pathway. This article details the current clinical experience with ibrutinib in the treatment of patients with MCL, including completed and published clinical trials and reviews potential adverse events (AEs) and pitfalls associated with ibrutinib therapy. Although most AEs experienced by patients treated with ibrutinib are mild, some can be severe and treatment limiting and may be attributed to off-target effects. Ibrutinib is a very promising agent for patients with MCL with notable response rates. However, when used as a single agent, around one third of patients relapse in the first 2 years of treatment. Recently reported combination therapies have shown significant activity. Emerging data evaluating potential mechanisms of drug resistance and the poor clinical outcomes after treatment failure are also discussed. Further understanding of resistance and its implications not only in relapsed disease but in the frontline setting are needed. Investigation of strategies to overcome resistance remains an area of high unmet clinical need. Evaluation of the impact of shorter treatment duration, effects on minimal residual disease, and incorporation of novel combinations are also warranted.",
keywords = "adverse events, ibrutinib, mantle cell lymphoma, resistance",
author = "Stephens, {Deborah M.} and Stephen Spurgeon",
year = "2015",
doi = "10.1177/2040620715592569",
language = "English (US)",
volume = "6",
pages = "242--252",
journal = "Therapeutic Advances in Hematology",
issn = "2040-6207",
publisher = "Sage Publications",
number = "5",

}

TY - JOUR

T1 - Ibrutinib in mantle cell lymphoma patients

T2 - Glass half full? Evidence and opinion

AU - Stephens, Deborah M.

AU - Spurgeon, Stephen

PY - 2015

Y1 - 2015

N2 - Mantle cell lymphoma (MCL) is a rare subtype of non-Hodgkin's lymphoma typically marked by an aggressive clinical course and a predilection for relapse. The B-cell receptor (BCR) signaling survival pathway is chronically activated in MCL, contributing to its pathogenesis. Ibrutinib is an inhibitor of Bruton's tyrosine kinase, a vital component of this pathway. This article details the current clinical experience with ibrutinib in the treatment of patients with MCL, including completed and published clinical trials and reviews potential adverse events (AEs) and pitfalls associated with ibrutinib therapy. Although most AEs experienced by patients treated with ibrutinib are mild, some can be severe and treatment limiting and may be attributed to off-target effects. Ibrutinib is a very promising agent for patients with MCL with notable response rates. However, when used as a single agent, around one third of patients relapse in the first 2 years of treatment. Recently reported combination therapies have shown significant activity. Emerging data evaluating potential mechanisms of drug resistance and the poor clinical outcomes after treatment failure are also discussed. Further understanding of resistance and its implications not only in relapsed disease but in the frontline setting are needed. Investigation of strategies to overcome resistance remains an area of high unmet clinical need. Evaluation of the impact of shorter treatment duration, effects on minimal residual disease, and incorporation of novel combinations are also warranted.

AB - Mantle cell lymphoma (MCL) is a rare subtype of non-Hodgkin's lymphoma typically marked by an aggressive clinical course and a predilection for relapse. The B-cell receptor (BCR) signaling survival pathway is chronically activated in MCL, contributing to its pathogenesis. Ibrutinib is an inhibitor of Bruton's tyrosine kinase, a vital component of this pathway. This article details the current clinical experience with ibrutinib in the treatment of patients with MCL, including completed and published clinical trials and reviews potential adverse events (AEs) and pitfalls associated with ibrutinib therapy. Although most AEs experienced by patients treated with ibrutinib are mild, some can be severe and treatment limiting and may be attributed to off-target effects. Ibrutinib is a very promising agent for patients with MCL with notable response rates. However, when used as a single agent, around one third of patients relapse in the first 2 years of treatment. Recently reported combination therapies have shown significant activity. Emerging data evaluating potential mechanisms of drug resistance and the poor clinical outcomes after treatment failure are also discussed. Further understanding of resistance and its implications not only in relapsed disease but in the frontline setting are needed. Investigation of strategies to overcome resistance remains an area of high unmet clinical need. Evaluation of the impact of shorter treatment duration, effects on minimal residual disease, and incorporation of novel combinations are also warranted.

KW - adverse events

KW - ibrutinib

KW - mantle cell lymphoma

KW - resistance

UR - http://www.scopus.com/inward/record.url?scp=84993709279&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84993709279&partnerID=8YFLogxK

U2 - 10.1177/2040620715592569

DO - 10.1177/2040620715592569

M3 - Review article

AN - SCOPUS:84993709279

VL - 6

SP - 242

EP - 252

JO - Therapeutic Advances in Hematology

JF - Therapeutic Advances in Hematology

SN - 2040-6207

IS - 5

ER -